guest column

Cultivating an office culture can prevent loneliness, create connections, says Houston expert

It’s important to remember that there’s no one-size-fits-all solution to balancing employee flexibility with returning to the office. Photo via Getty Images

There’s been a lot of chatter about returning to the office and remote work. No matter which side of the argument you’re on, there are valid points to be made for both views. The pandemic forced organizations to rethink operations, with many employees working remote for the first time. And now, we’re in that habit and many don’t want to change.

But here’s the thing. Isolation creates loneliness and we’re in the middle of a loneliness epidemic. A report released by The U.S. Surgeon General titled “Our Epidemic of Loneliness and Isolation,” found that even before COVID changed the world, about half of the U.S. adults reported experiencing measurable levels of loneliness. While technology has allowed for work to continue outside of traditional office walls by dialing in to video conferences from home, there is still a missing link. It’s much harder to build community virtually. We haven’t cracked that code yet.

Sen. Chris Murphy, D – Conn, recently introduced legislation to create a national policy to promote social connection and address the soaring rates of loneliness.

“Loneliness is one of the most serious, misunderstood problems facing America today,” Murphy said in a press statement. “This crisis transcends traditional political boundaries, presenting a chance to bring together right and left around a project to help people find connectedness.”

Whether people realize it or not, we all need to feel seen and understood, and when that happens it creates meaningful connection. That connection in turn leads to strong company culture and more productive, energizing workdays.

Happiness begins with healthy human relationships and companies are being challenged to balance employee flexibility and workplace interactions. While there is no clear-cut right answer, Birkman International is moving to a four-day, in-office workweek. Employees will cut back from 40 to 32 hours-per-week and those hours will be spent at Birkman’s offices.

With employees once again working under the same roof, there will be opportunities for organic spot meetings, team brainstorms and water cooler chatter. While some might see these as “soft” skills, they are essential for a well-performing workplace.

It’s important to remember that there’s no one-size-fits-all solution to balancing employee flexibility with returning to the office. Just like every person has unique needs, every company must figure the best solution for its culture, its productivity and most importantly, its people.

------

Amy Shepley serves as president at Birkman International, an industry-leading organizational performance company.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted